Bioavailability analysis of polychlorinated dibenzo-p-dioxins (PCDDs) and dibenzofurans (PCDFs) determines the fraction of soil-bound dioxins that can actually be absorbed by humans and wildlife, providing a scientifically defensible basis for accurate risk assessment. This technical article explains the underlying principles, testable sample types, analytical parameters, standard testing methods, and practical applications of dioxin bioavailability analysis for environmental consultants, regulators, and researchers.
Technical Overview
Dioxins, comprising polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs), are persistent, highly lipophilic organic pollutants formed primarily as unintentional by-products of combustion, waste incineration, metallurgical processes, and historical chlorinated chemical manufacturing. Of the 210 theoretically possible congeners, only the seventeen 2,3,7,8-substituted PCDD/Fs exhibit significant dioxin-like toxicity, and each is assigned a toxic equivalency factor (TEF) by the World Health Organization, with 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) as the reference compound. Total toxicity is conventionally expressed as the toxic equivalent (TEQ).
Bioavailability refers to the fraction of an ingested or inhaled dose of a contaminant that reaches systemic circulation and becomes available at the site of toxicological action. Because dioxins in soil and dust are strongly sorbed onto organic matter and black carbon, only a portion of the total measured concentration is actually released during gastrointestinal digestion and subsequently absorbed. Conventional risk assessments often assume complete absorption, which can substantially overestimate actual exposure.
Bioavailability analysis quantifies this absorbed fraction and replaces default conservative assumptions with site-specific values. Several interrelated concepts are central to the discipline:
- Absolute bioavailability: the fraction of an administered dose that reaches the bloodstream, typically determined through in vivo studies.
- Relative bioavailability (RBA): the comparative absorption of a contaminant from a test matrix, such as soil, relative to a reference medium such as food or corn oil, expressed as a percentage.
- Bioaccessibility: the maximum fraction of the contaminant that dissolves in simulated gastrointestinal fluids and is therefore potentially available for intestinal uptake, serving as an in vitro surrogate for bioavailability.
By integrating bioavailability data into exposure models, risk assessors can derive realistic cleanup goals, prioritize remediation resources, and reduce unnecessary remediation costs at contaminated sites.
Testing Samples
Soil and Sediment
Surface and subsurface soils from industrial sites, former pesticide and chlor-alkali plants, wood-treatment facilities using pentachlorophenol, e-waste dismantling zones, and recreational or residential areas, as well as river, lake, and estuarine sediments. Samples are typically air-dried or freeze-dried, gently crushed, homogenized, and sieved to below 250 micrometers to represent the particle fraction most likely to adhere to skin and be inadvertently ingested, particularly by children.
Indoor Dust and Airborne Particulate Matter
Settled indoor dust, vacuum dust, street dust, and PM10 or PM2.5 collected on quartz or Teflon filters. These matrices are critical for evaluating the indoor ingestion and inhalation exposure pathway and for assessing hand-to-mouth transfer scenarios in residential environments near emission sources.
Fly Ash and Incineration Residues
Fly ash, bottom ash, and air-pollution-control residues from municipal solid waste incinerators, hazardous waste incinerators, and sinter plants. Testing these residues supports occupational exposure evaluation, disposal classification, and assessment of treatment technologies such as vitrification or cement solidification.
Food, Feed, and Biological Matrices
fish, meat, eggs, dairy products, animal feed, human serum, breast milk, and adipose tissue. These matrices confirm systemic exposure in target receptors, validate bioavailability estimates derived from in vitro or in vivo models, and verify compliance with food and feed safety limits.
Testing Items
Standard analytical packages for dioxin bioavailability studies typically include the following deliverables:
- Congener-specific quantification of all seventeen 2,3,7,8-substituted PCDD/F congeners.
- Total concentrations expressed in nanograms per kilogram and as WHO-TEQ using the applicable TEF scheme.
- Gastrointestinal bioaccessible fraction of total TEQ and of individual congeners, expressed as a percentage of the total.
- Relative bioavailability values derived from in vivo assays or validated in vitro-in vivo correlation models.
- Optional extension to the twelve dioxin-like polychlorinated biphenyls (dl-PCBs) and polybrominated dioxins and furans (PBDD/Fs).
- Congener profiles and homologue fingerprints for source identification and forensic attribution.
Testing Methods
Sample Preparation and Extraction
Dried and sieved samples are spiked with a full suite of carbon-13 labeled internal standards in accordance with EPA Method 1613B. Extraction is performed by Soxhlet, automated Soxhlet, or pressurized liquid extraction using toluene or toluene-hexane mixtures. Multi-stage column cleanup, employing multilayer acid-base silica, Florisil, alumina, and activated carbon, removes matrix interferences and separates PCDD/Fs from co-extracted organochlorine compounds prior to instrumental analysis.
In Vitro Bioaccessibility Testing
Bioaccessibility is evaluated using physiologically based gastrointestinal digestion models, including the Unified Bioaccessibility Method (UBM) described in ISO 17924, the German DIN 19738 method, the RIVM in vitro digestion model, and the physiologically based extraction test (PBET). The test material is incubated sequentially at 37 degrees Celsius in synthetic gastric fluid containing pepsin at acidic pH, followed by intestinal fluid containing pancreatin and bile salts at near-neutral pH. The resulting chyme is separated by centrifugation and ultrafiltration, and the dissolved PCDD/F fraction in the fluid phase is solvent-extracted and quantified separately from the residual solid. Bioaccessibility is calculated as the dissolved TEQ divided by the total TEQ, multiplied by one hundred. Where validated correlations exist, in vitro data are converted to relative bioavailability estimates.
In Vivo Relative Bioavailability Studies
Animal assays, most commonly using juvenile swine or mice, compare the absorption of dioxins from the contaminated soil matrix against a reference medium such as corn oil or spiked feed. Relative bioavailability is derived from the area under the curve of congener concentrations in serum or adipose tissue, or from fecal mass-balance calculations. These studies are conducted under Good Laboratory Practice conditions and institutional ethical approval, and they remain the reference approach for regulatory acceptance of bioavailability-adjusted risk assessments.
Instrumental Analysis
Confirmatory quantification is performed by isotope-dilution high-resolution gas chromatography coupled with high-resolution mass spectrometry (HRGC/HRMS) following EPA Method 1613B, EPA Method 8290A, or European Standard EN 1948. Chromatographic separation uses non-polar fused-silica columns, and the mass spectrometer operates at a resolution of at least 10,000 while monitoring two characteristic ions per congener. Method detection limits reach the sub-picogram TEQ per gram level for soils. Quality assurance includes method blanks, ongoing precision and recovery standards, duplicate analyses, and labeled-standard recovery within EPA-specified control limits, typically 40 to 135 percent.
Bioanalytical Screening
For cost-effective screening of large sample batches and rapid evaluation of digestion supernatants, dioxin-responsive chemically activated luciferase expression (DR-CALUX) assays or EROD bioassays may be employed. These reporter-gene systems report total dioxin-like activity as bioanalytical equivalents (BEQ) within approximately three working days, with HRGC/HRMS confirmation reserved for samples exceeding screening thresholds.
Applications
Bioavailability analysis of dioxins supports a wide range of environmental and public health decision contexts:
- Refined human health risk assessment, in which site-specific relative bioavailability replaces default assumptions and frequently reduces calculated exposure by a factor of two to ten.
- Derivation of site-specific remediation goals by back-calculating cleanup levels from bioavailability-adjusted exposure estimates.
- Regulatory compliance and brownfield redevelopment due diligence, aligned with frameworks such as the Stockholm Convention, national soil environmental standards, and risk-based corrective action guidance.
- Performance verification of remediation technologies, including sorbent amendment with biochar or activated carbon designed to reduce the bioavailable dioxin pool in soils and sediments.
- Food and feed safety verification against European Union maximum limits and Codex Alimentarius guidance.
- Litigation support and source apportionment based on congener fingerprints combined with bioavailability evidence.
- Academic and regulatory research into the toxicokinetics, maternal transfer, and long-term fate of dioxins in environmental and biological systems.
FAQ
What is the difference between bioaccessibility and bioavailability?
Bioaccessibility is the fraction of the contaminant that dissolves in synthetic gastrointestinal fluids and is therefore potentially absorbable, measured entirely in vitro. Bioavailability is the fraction that actually reaches systemic circulation and is typically measured in vivo. Bioaccessibility provides an upper-bound, ethically preferable, and less expensive surrogate for bioavailability when validated correlations are applied.
Why perform bioavailability analysis when total dioxin concentrations can already be measured?
Total concentration measurements alone assume that all dioxins present in a matrix are fully absorbed. Because strong sorption to soil organic matter and black carbon limits release during digestion, this assumption overestimates risk for many field soils. Bioavailability data allow risk assessors to use realistic absorption values, potentially avoiding multimillion-dollar over-remediation while maintaining protectiveness.
Should an in vitro or an in vivo method be selected?
In vitro digestion methods such as UBM are faster, cheaper, and suitable for screening and for large sample sets. In vivo swine or mouse studies provide the most defensible relative bioavailability values for regulatory negotiations at high-stakes sites. A tiered approach, screening with in vitro tests and confirming with in vivo assays on representative samples, is commonly recommended.
How much sample is required and what detection limits can be achieved?
A typical program requires 10 to 50 grams of dried, sieved soil or dust for combined bioaccessibility and confirmatory analysis. Using EPA 1613B HRGC/HRMS procedures, method detection limits of 0.1 to 1 picogram WHO-TEQ per gram are routinely achieved for soils, sufficient for most risk assessment scenarios.
How are results reported?
Final reports present congener-specific concentrations, total WHO-TEQ values, bioaccessible and relative bioavailability percentages, complete quality control data including labeled-standard recoveries, method blank results, and duplicate precision, together with an interpretation of how the derived bioavailability values should be applied in site-specific exposure calculations.